Marginal zone lymphoma (MZL) is a slow-growing cancer of the immune system that develops from a type of white blood cell called a B-cell. It accounts for roughly 5% to 10% of all non-Hodgkin lymphomas and gets its name from the “marginal zone,” a specific region in lymph tissue where these B-cells normally live. Median survival exceeds 10 years, making it one of the more treatable lymphomas, though the experience varies significantly depending on which subtype you have and where in the body it develops.
Where It Starts in the Immune System
Your lymph nodes, spleen, and other lymphoid tissues contain organized zones where immune cells mature and learn to fight infections. The marginal zone sits at the outer edge of these structures, surrounding a region called the germinal center where B-cells are trained to produce antibodies. In MZL, mature B-cells in this zone begin multiplying uncontrollably instead of doing their normal immune work.
These cancerous cells show signs of having already passed through the germinal center’s “training program.” About 85% of cases carry genetic changes called somatic hypermutation, a hallmark of B-cells that have already learned to respond to infections. In many cases, a key cellular signaling pathway (called NF-κB) becomes permanently switched on, pushing these cells to keep growing when they should stop. This can happen through genetic mutations that disable the body’s built-in brakes on that pathway.
Three Subtypes With Different Behaviors
MZL is actually three distinct diseases grouped under one name, each arising in a different part of the body.
MALT Lymphoma (Extranodal)
This is by far the most common form, making up about 70% of all MZL cases. MALT stands for mucosa-associated lymphoid tissue, and these lymphomas grow in organs that aren’t traditionally part of the lymph system: the stomach, lungs, eyes, thyroid, and skin. The stomach is the single most frequent site. MALT lymphomas tend to stay localized for long periods, though up to 25% of cases eventually spread to other sites, particularly when the lymphoma starts outside the stomach. The five-year relative survival rate is 93.8%, the highest of the three subtypes.
Splenic Marginal Zone Lymphoma
This subtype accounts for about 20% of cases and develops in the spleen. It frequently spreads to the bone marrow, with biopsy-confirmed marrow involvement in over 80% of patients. Despite that high rate of spread, five-year relative survival is still 85.3%. Splenic MZL is sometimes linked to hepatitis C infection.
Nodal Marginal Zone Lymphoma
The rarest form at roughly 10% of cases, nodal MZL grows in the lymph nodes themselves. Swollen lymph nodes in the head and neck area are a common first sign, with about one-third of patients having tumors larger than 5 cm at diagnosis. Around half already have advanced-stage disease when it’s found. Bone marrow involvement occurs in about 51% of patients. The five-year relative survival rate is 82.8%.
Infections and Autoimmune Triggers
MZL stands out from many other cancers because specific, identifiable triggers are known for a significant number of cases. Chronic infections force the immune system’s B-cells to keep dividing, and occasionally that persistent stimulation tips a cell toward becoming cancerous.
The best-understood link is between the stomach bacterium H. pylori and gastric MALT lymphoma. Other infections connected to MZL at various body sites include hepatitis C (linked to splenic MZL), Chlamydophila psittaci (eye), Campylobacter jejuni (small intestine), and Borrelia burgdorferi, the bacterium behind Lyme disease (skin).
Autoimmune conditions also raise risk. Hashimoto’s thyroiditis, which attacks the thyroid, and Sjögren’s syndrome, which targets moisture-producing glands, both involve years of immune system overactivity in specific tissues. That chronic inflammation creates the same kind of environment where B-cells can eventually turn malignant.
Symptoms by Subtype
MZL often develops quietly. Many people have no symptoms at all, and the lymphoma is found incidentally during tests for something else. When symptoms do appear, they depend heavily on where the disease is growing.
Gastric MALT lymphoma can cause indigestion, stomach pain, nausea, or a feeling of fullness, symptoms easily mistaken for a routine ulcer or gastritis. MALT lymphomas in other locations may show up as a lump, a persistently red eye, a skin lesion, or breathing changes if the lungs are involved. Splenic MZL often presents as an enlarged spleen, which you might notice as discomfort or fullness in the upper left side of your abdomen. Nodal MZL typically shows up as painless, swollen lymph nodes.
Systemic symptoms like drenching night sweats, unexplained fevers, and unintentional weight loss (sometimes called “B symptoms”) can occur but are less common in MZL than in more aggressive lymphomas.
How It’s Diagnosed
Diagnosis requires a tissue biopsy, usually from the affected organ, lymph node, or bone marrow. Pathologists look at the cells under a microscope and run a panel of tests to identify specific proteins on the cell surface. MZL cells typically express a protein called CD20 (important because it’s also a treatment target) while lacking two markers, CD5 and CD10, that are characteristic of other lymphoma types. The absence of CD23 helps rule out a different slow-growing lymphoma called CLL/SLL.
Staging determines how far the disease has spread. A CT scan is generally sufficient for most patients. PET-CT, which highlights metabolically active areas, is typically reserved for cases where doctors suspect the lymphoma may have transformed into a more aggressive type. For MALT lymphoma that appears localized, bone marrow biopsy can sometimes be skipped if blood counts are normal, since fewer than 10% of these patients have marrow involvement.
Prognostic scoring tools help predict outcomes. For MALT lymphoma, the MALT International Prognostic Index uses three factors: advanced stage disease, age 70 or older, and elevated levels of a blood enzyme called LDH.
Treatment Approaches
Treatment for MZL is not one-size-fits-all. It ranges from treating an underlying infection to using advanced cell therapies, depending on the subtype, stage, and how much the disease is affecting your daily life.
Treating the Underlying Cause
For gastric MALT lymphoma associated with H. pylori, the first step is a course of antibiotics to clear the infection. In a substantial number of early-stage cases, eliminating the bacteria causes the lymphoma itself to regress without any cancer-directed treatment. Similarly, treating hepatitis C can lead to improvement in some cases of splenic MZL.
Watchful Waiting
If the disease is advanced but causing minimal symptoms and has a low tumor burden, doctors may recommend active monitoring rather than immediate treatment. This isn’t neglect; it reflects the lymphoma’s slow growth and the fact that starting therapy earlier doesn’t necessarily improve long-term outcomes for indolent disease. You’ll have regular check-ups and blood work, with treatment beginning if the disease progresses or symptoms develop.
Radiation Therapy
For localized disease, radiation is highly effective. Even ultra-low doses (as little as 4 Gy, compared to the traditional 24 Gy) have shown promising results for MALT lymphoma, particularly in the stomach. Radiation tends to produce durable local control with relatively limited side effects when the disease is confined to one area.
Immunotherapy and Chemotherapy
When treatment is needed for more widespread disease, the combination of an immune-targeting drug (rituximab, which attacks the CD20 protein on lymphoma cells) with chemotherapy is a standard approach. This combination has been studied against other common regimens and shown comparable or better results with a generally manageable side-effect profile. Current treatment decisions for MZL are still largely guided by single-arm studies, meaning head-to-head comparisons remain limited.
Targeted and Cell-Based Therapies
For patients whose lymphoma returns after two or more rounds of treatment, newer options exist. The FDA has approved CAR T-cell therapy (lisocabtagene maraleucel, marketed as Breyanzi) specifically for relapsed or refractory MZL. This treatment involves collecting your own immune cells, genetically engineering them in a lab to recognize and attack the lymphoma, and infusing them back into your body. It received both Priority Review and Orphan Drug designation, reflecting the need for effective options in this space.
Living With a Slow-Growing Lymphoma
Because MZL grows slowly and median survival extends beyond a decade, many people live with this diagnosis for years or even decades. That long timeline brings its own challenges. Some patients find the “watch and wait” period psychologically difficult, feeling uneasy about carrying a cancer that isn’t being actively treated. Others deal with the reality that while MZL responds well to treatment, it can relapse, sometimes requiring multiple lines of therapy over the years.
The risk of transformation into a more aggressive lymphoma exists but is relatively uncommon. A sudden change in symptoms, rapid lymph node growth, new B symptoms, or a sharp rise in LDH levels can signal this shift and warrants prompt evaluation. Regular follow-up, even during periods of remission, remains important for catching any changes early.